MARKET

PBYI

PBYI

Puma Biotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.52
-0.61
-5.03%
After Hours: 11.66 +0.14 +1.18% 16:07 12/04 EST
OPEN
12.19
PREV CLOSE
12.13
HIGH
12.38
LOW
11.42
VOLUME
493.95K
TURNOVER
--
52 WEEK HIGH
15.00
52 WEEK LOW
5.50
MARKET CAP
458.06M
P/E (TTM)
-8.0814
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Puma Biotechnology says European patent board upholds patent covering EGFR inhibitors
Puma Biotechnology ([[PBYI]] -5.7%) said the European Board of Appeals has rejected the opposition to EP Patent 1848414 initiated by a Boehringer Ingelheim entity.EP Patent 1848414, originally granted in April
Seekingalpha · 2d ago
Puma Biotechnology Says Has Prevailed In Proceedings Against European EP Patent 1848414; European Board Of Appeals Rejected Opposition Of Patent By A Boehringer Ingelheim Entity
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which covers the use of
Benzinga · 2d ago
Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted
European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.
Business Wire · 2d ago
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Puma Biotechnology will present 10 posters at the 2020 Virtual San Antonio Breast Cancer Symposium, which will be held Dec. 8-11, 2020.
Business Wire · 11/17 21:15
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from Dec 8-11, 2020. Abstracts are available to the public online on the SABCS website at www.sabcs.org.
BusinessWire · 11/17 18:15
Puma Biotechnology, Inc. (NASDAQ:PBYI) Just Reported Earnings, And Analysts Cut Their Target Price
As you might know, Puma Biotechnology, Inc. (NASDAQ:PBYI) last week released its latest quarterly, and things did not...
Simply Wall St. · 11/09 11:42
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 3, 2020 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,750 shares of Puma common stock to 5 new non-executive employees.
BusinessWire · 11/06 18:30
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06 12:47
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PBYI. Analyze the recent business situations of Puma Biotec through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PBYI stock price target is 10.33 with a high estimate of 16.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 231
Institutional Holdings: 42.33M
% Owned: 106.45%
Shares Outstanding: 39.76M
TypeInstitutionsShares
Increased
36
3.38M
New
46
2.20M
Decreased
44
4.37M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.87%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
Chairman/Chief Executive Officer/President/Director
Alan Auerbach
Chief Financial Officer
Maximo Nougues
Senior Vice President
Douglas Hunt
Chief Scientific Officer
Richard Bryce
Lead Director/Independent Director
Jay Moyes
Director
Brian Stuglik
Independent Director
Ann Miller
Independent Director
Michael Miller
Independent Director
Hugh O Dowd
Independent Director
Adrian Senderowicz
Independent Director
Troy Wilson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib, oral), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Puma Biotechnology Inc stock information, including NASDAQ:PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.